UNSPSC 51283725: Cefuroxime pivoxetil

This classification denotes a cephalosporin antibiotic C23H28N4O11S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LR90117565, chemically known as 1-hydroxyethyl (6r,7r)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7^2-(z)-(o-methyloxime), 3-carbamate 1-(2-methoxy-2-methylpropionate), but more generally known as cefuroxime pivoxetil, which bears US NIH Compound Identifier 9595289.

Most nations, for tariff and trade purposes, schedule cefuroxime pivoxetil under HS 29419000 and SITC 54139. As of Q4 2014, CEFUROXIME PIVOXETIL remains US FDA's Preferred Term for this commodity. Cefuroxime pivoxetil bears US NLM identifiers UMLS ID C2699152 and NCI Concept Code C76178. SMILES: CC(OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N\OC)/C3CCCO3)COC(=O)N)OC(=O)C(C)(C)OC.

UNSPSC 51283725 Cefuroxime pivoxetil is a Commodity code that nominally describes a single antibiotic pharmaceutical product, but recent state and local solicitations show little relevant activity under this specific code. The three opportunities posted in the source—Seminole County's naloxone and drug deactivation systems procurement, Texas HHS's therapeutic pharmacy initiative RFI, and the City of Tampa's medical and first aid supplies IFB—do not target cefuroxime pivoxetil or narrow-spectrum antibiotic products. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products is the only opportunity tangentially aligned with pharmaceutical procurement broadly, but it seeks manufacturers willing to supply unspecified generic drugs through authorized wholesalers, not cefuroxime pivoxetil as a line item. State and local governments do procure pharmaceuticals through cooperative purchasing vehicles and direct competitive bidding, but the available evidence does not support active, sustained demand for this specific antibiotic at the state or local level.

The geographic spread of pharmaceutical activity shown in the source spans Texas, Minnesota (with Oregon as a cooperative participant), and Florida, but none of these opportunities target cefuroxime pivoxetil directly. The most recent solicitations—Seminole County's naloxone IFB (response date July 26, 2023), Texas HHS's pharmacy RFI (April 3, 2026), Tampa's medical and first aid supplies IFB (March 13, 2026), and MMCAP's generic pharmaceuticals RFP (March 26, 2026)—reflect procurement activity in emergency response, broad-spectrum generic pharmaceuticals, and first-aid consumables, not oral cephalosporin antibiotics. Unless state and local demand for cefuroxime pivoxetil has been tagged inconsistently across procurement systems, this code shows no current market activity worth pursuing.